Research location

Bottrop

Germany

Published trials61

Site observations68

Linked trials published61

Page1 / 2

Research activity in Bottrop

Germany

CureCurrent currently publishes aggregate city-level research activity for this location: 61 trials and 68 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Bottrop

61 linked trials · page 1 of 2

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerNCT07287098 · 2026-05-13 · 1 site observation

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22 · 1 site observation

Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's DiseaseNCT07151378 · 2025-10-27 · 1 site observation

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 · 2025-08-26 · 1 site observation

A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceNCT06830720 · 2025-02-20 · 1 site observation

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerNCT06201234 · 2024-12-13 · 1 site observation

Phase IIIb Study of Ribociclib + ET in Early Breast CancerNCT05827081 · 2024-02-28 · 1 site observation

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)NCT05512364 · 2023-12-15 · 1 site observation

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerNCT05894239 · 2023-09-08 · 1 site observation

Magseed Pro(R)/ Sentimag(R) Gen3NCT05142787 · 2023-03-02 · 1 site observation

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsNCT05232916 · 2022-12-16 · 1 site observation

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 1 site observation

PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFSNCT05792150 · 2022-12-07 · 1 site observation

The AFteR Registry - Follow-up Study to Monitor the Efficacy and Safety of the Occlutech AFR in Heart Failure PatientsNCT04405583 · 2020-10-28 · 1 site observation

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone TherapyNCT06440967 · 2024-07-31 · 1 site observation

ACTIVE_NOT_RECRUITING

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast CancerNCT06172127 · 2024-07-22 · 1 site observation

ACTIVE_NOT_RECRUITING

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's DiseaseNCT06107426 · 2024-01-24 · 1 site observation

ACTIVE_NOT_RECRUITING

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyNCT05840211 · 2023-05-08 · 1 site observation

ACTIVE_NOT_RECRUITING

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to SurgeryNCT05549505 · 2023-02-15 · 1 site observation

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)NCT05306340 · 2022-08-03 · 1 site observation

ACTIVE_NOT_RECRUITING

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382286 · 2022-07-25 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyNCT04873362 · 2021-05-04 · 1 site observation

ACTIVE_NOT_RECRUITING

Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX TherapyNCT04770272 · 2021-03-01 · 1 site observation

Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients With rCR and pCR in the Breast After NASTNCT04101851 · 2021-01-13 · 1 site observation

ACTIVE_NOT_RECRUITING

Sacituzumab Govitecan in Primary HER2-negative Breast CancerNCT04595565 · 2020-10-28 · 1 site observation

ACTIVE_NOT_RECRUITING

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.NCT04767594 · 2020-10-27 · 3 site observations

ACTIVE_NOT_RECRUITING

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast CancerNCT04478266 · 2020-10-14 · 1 site observation

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast CancerNCT03901339 · 2019-05-08 · 1 site observation

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerNCT03701334 · 2018-12-07 · 1 site observation

ACTIVE_NOT_RECRUITING

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast CancerNCT03595592 · 2018-09-07 · 1 site observation

ACTIVE_NOT_RECRUITING

Re-evaluation of Optimal Re-synchronisation Therapy in Patients With Chronic Heart FailureNCT03494933 · 2018-09-01 · 1 site observation

A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line TreatmentNCT06311383 · 2017-10-09 · 1 site observation

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerNCT02947685 · 2017-06-21 · 1 site observation

ACTIVE_NOT_RECRUITING

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast CancerNCT03096847 · 2016-10-24 · 1 site observation

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or FulvestrantNCT02894398 · 2016-09-06 · 1 site observation

PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLCNCT02777658 · 2016-05-26 · 1 site observation

PALbociclib CoLlaborative Adjuvant StudyNCT02513394 · 2015-08-01 · 1 site observation

ACTIVE_NOT_RECRUITING

Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation TherapyNCT02173769 · 2014-06-01 · 2 site observations

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerNCT02032823 · 2014-04-22 · 1 site observation

ACTIVE_NOT_RECRUITING

Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD RegimenNCT01985334 · 2014-02-14 · 1 site observation

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast CancerNCT01958021 · 2013-12-17 · 1 site observation

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast CancerNCT01548677 · 2013-04-01 · 1 site observation

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based TreatmentNCT01702571 · 2012-11-27 · 1 site observation

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast CancerNCT01626222 · 2012-06-01 · 1 site observation

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)NCT01585298 · 2012-04-29 · 1 site observation

Treatment Study of Negative Pressure Wound Therapy for Diabetic Foot WoundsNCT01480362 · 2011-11-01 · 1 site observation

Study of ExAblate Focused Ultrasound Ablation of Breast CancerNCT01620359 · 2010-11-24 · 1 site observation

Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA)NCT01285167 · 2010-08-01 · 2 site observations

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin TreatmentNCT01125566 · 2010-06-22 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.